A new combination of drugs and chemotherapy could offer a ‘new standard of care’ for certain types of digestive system cancer

Zolbetuximab plus mFOLFOX6—a chemotherapy combination commonly used in gastric cancer—significantly prolonged patients’ progression-free survival compared with mFOLFOX6 alone in patients with CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric/gastroesophageal junction ( GEJ) adenocarcinoma, according to primary phase 3 data from the SPOTLIGHT trial. The results, presented during the 2023 Gastrointestinal Cancer Symposium, a conference organized …

A new combination of drugs and chemotherapy could offer a ‘new standard of care’ for certain types of digestive system cancer Read More »